hotspot -WSS

hotspot

author：entertainment 2025-09-27 18:37:28 - browse：27355

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： The most pressing bird flu mysteries scientists want answered

focus

WSS

Elevance PBM president out as customers face prescription chaos

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Venture capitalist Bob Kocher on the state of digital health

hotspot

hotspot

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

How to save PrEP access — and even expand it

Congress needs to close a vaccine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Psychedelics group wrestles with new pharma identity

Eli Lilly’s Zepbound improved liver scarring in mid

BioMarin wins approval for gene therapy to treat hemophilia A

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

The most pressing bird flu mysteries scientists want answered

FTC loses bid to block Novant's North Carolina hospital merger

Anthony Fauci pushes back on GOP claims during Covid hearing

Data integrity in scientific journals requires "effort" by publishers, institutions

Sutter Health’s antitrust win overturned by appeals court

knowledge

focus

hotspot

focus